{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:01:57Z","timestamp":1792929717253,"version":"4.5.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) is a heterogeneous disease exemplified by focal lesions (FLs), densely populated nodules whose number and persistence during treatment predict poor outcome. However, the prognostic role of FL location and the relationship between FLs at different time points remain underexplored, although they may provide critical clues to disease evolution and resistance mechanisms. We analyzed positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging (DWI) scans from 243 patients with MM enrolled in total therapies at baseline, after autologous stem cell transplant (ASCT), and every 6 to 12 months thereafter until relapse or last follow-up. Baseline FLs in the humerus or femur were associated with poor prognosis. Although rare, residual PET-positive FLs after ASCT identified patients with worse outcomes. One-third of patients had residual FLs on DWI after ASCT, which also correlated with poor prognosis. Even FLs that resolved after the second ASCT in patients who underwent tandem ASCTs retained adverse prognostic significance, highlighting the limitations of late imaging in high-risk patients. Patients who achieved both minimal residual disease (MRD) and imaging negativity after ASCT had the best outcomes. Conversely, MRD-negative patients with FLs had as poor outcomes as double-positive patients. Residual FLs persisting to relapse were predominantly observed in early relapse cases, and resolved FLs frequently recurred at the same or nearby sites, suggesting limited imaging sensitivity for detection of focal resistant cells. Taken together, this study identifies long bone FLs as a risk factor, and underscores the value of serial imaging and the urgent need for alternative treatment strategies for patients with persistent FLs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016510","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:52:59Z","timestamp":1751367179000},"page":"4368-4377","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET\/DWI imaging"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"first","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, University Hospital of W\u00fcrzburg, Germany"},{"name":"3Mildred Scheel Early Career Center, University Hospital of W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Ashby","sequence":"additional","affiliation":[{"name":"4Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"van Hemert","sequence":"additional","affiliation":[{"name":"5Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde","family":"Bailey","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy V.","family":"Alapat","sequence":"additional","affiliation":[{"name":"6Department of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-2973","authenticated-orcid":false,"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology Myeloma Center, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-3234","authenticated-orcid":false,"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[{"name":"7Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"8Clinical Cooperation Unit Molecular Hematology\/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"10 272","key":"2025090815213098300_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2025090815213098300_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"2025090815213098300_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.hoc.2023.12.012","article-title":"Impact of clonal heterogeneity in multiple myeloma","author":"Schinke","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2025090815213098300_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"issue":"23","key":"2025090815213098300_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.V126.23.371.371","article-title":"Spatiotemporal analysis of intraclonal heterogeneity in multiple myeloma: unravelling the impact of treatment and the propagating capacity of subclones using whole exome sequencing","volume":"126","author":"Melchor","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2025090815213098300_bib6","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"2025090815213098300_bib7","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","article-title":"Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma","volume":"97","author":"Hillengass","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"2025090815213098300_bib8","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2025090815213098300_bib9","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2025090815213098300_bib10","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2025090815213098300_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025090815213098300_bib12","doi-asserted-by":"crossref","first-page":"116857","DOI":"10.1016\/j.bone.2023.116857","article-title":"Identification of focal lesion characteristics in MRI which indicate presence of corresponding osteolytic lesion in CT in patients with multiple myeloma","volume":"175","author":"Hildenbrand","year":"2023","journal-title":"Bone"},{"issue":"9","key":"2025090815213098300_bib13","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.3390\/cancers12092537","article-title":"Spatial distribution of focal lesions in whole-body MRI and influence of MRI protocol on staging in patients with smoldering multiple myeloma according to the new SLiM-CRAB-criteria","volume":"12","author":"Wennmann","year":"2020","journal-title":"Cancers"},{"issue":"7","key":"2025090815213098300_bib14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: how? when?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2025090815213098300_bib15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2025090815213098300_bib16","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2025090815213098300_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2025090815213098300_bib18","doi-asserted-by":"crossref","first-page":"E230","DOI":"10.1002\/ajh.26995","article-title":"Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma","volume":"98","author":"Belotti","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2025090815213098300_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025090815213098300_bib20","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","article-title":"Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy","volume":"116","author":"van Rhee","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2025090815213098300_bib21","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1038\/bcj.2016.85","article-title":"Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma","volume":"6","author":"Jethava","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025090815213098300_bib22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2012.160","article-title":"Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured?","volume":"27","author":"Usmani","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"2025090815213098300_bib23","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.3324\/haematol.2017.165217","article-title":"The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype","volume":"102","author":"Schinke","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"2025090815213098300_bib24","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2025090815213098300_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V96.4.1505","article-title":"High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH","volume":"96","author":"Shaughnessy","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2025090815213098300_bib26","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"26","key":"2025090815213098300_bib27","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025090815213098300_bib28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025090815213098300_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"2025090815213098300_bib30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"issue":"19","key":"2025090815213098300_bib31","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2025090815213098300_bib32","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/RLU.0b013e3181b06bc5","article-title":"Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET","volume":"34","author":"Dimitrakopoulou-Strauss","year":"2009","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2025090815213098300_bib33","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"issue":"25","key":"2025090815213098300_bib34","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025090815213098300_bib35","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1038\/s41467-023-40584-4","article-title":"Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level","volume":"14","author":"John","year":"2023","journal-title":"Nat Commun"},{"issue":"17","key":"2025090815213098300_bib36","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.3390\/cancers13174323","article-title":"Prognostic value of FDG-PET\/CT parameters in patients with relapse\/refractory multiple myeloma before anti-CD38 based therapy","volume":"13","author":"Fouquet","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/17\/4368\/2409073\/blooda_adv-2025-016510-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/17\/4368\/2409073\/blooda_adv-2025-016510-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T19:21:41Z","timestamp":1757359301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/17\/4368\/537991\/Prognostic-impact-of-focal-lesion-location-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":36,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016510","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,9]]},"published":{"date-parts":[[2025,8,27]]}}}